Lilly to stop development of lymphoma drug enzastaurin

05/12/2013 | Genetic Engineering & Biotechnology News

Eli Lilly & Co. said it would stop developing the experimental drug enzastaurin as a treatment for diffuse large B-cell lymphoma after obtaining unfavorable results from a late-stage trial. The drug failed to significantly improve disease-free survival against placebo in patients at high risk of relapse after chemotherapy.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA
Senior Scientist - Cell Engineering Group
Pfizer
San Francisco, CA
Area Reimbursement Manager (CT, MA, MD, ME, NH, NJ, NY, PA, VT)
SI-BONE, INC
Multiple Locations, SL_Multiple Locations
Medical Director - Physician
Willamette Valley Community Health
Salem, OR
Medical Director - Physician
Willamette Valley Community Health
Salem, OR